ArticlePsychiatry research2023
Child and adolescent psychiatrists' use, attitudes, and understanding of genetic testing and pharmacogenetics in clinical practice.
Article in Psychiatry research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Genetic testing in psychiatry, the perceptions of healthcare workers and patients: a mini review.Frontiers in public health · 2024Pooled it
- Genetic Counselor Utilization Across Non-Genetics Departments for Neurodevelopmental Disorders.medRxiv : the preprint server for health sciences · 2026Article
- Genetic needs assessment of children with intellectual disability, developmental delay, hearing loss, and/or autism spectrum disorder.Pediatric research · 2026Article
- Patient Perspectives on Psychiatric Polygenic Risk Scores in Reproductive Decision-Making and Polygenic Embryo Screening.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2026Article
- What do European clinical guidelines say about genetic testing for people with neuropsychiatric disorders? A scoping review.Psychiatric genetics · 2026Article
- Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review: Child Psychiatry in the Era of Genomics: The Promise of Translational Genetics Research for the Clinic.JAACAP open · 2025Review
- Navigating the Future of Polygenic Risk Scores: Insights from Child and Adolescent Psychiatrists.Child psychiatry and human development · 2025Article
- Psychiatric polygenic risk scores: Experience, hope for utility, and concerns among child and adolescent psychiatrists.Psychiatry research · 2024Article
- Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices.Frontiers in pharmacology · 2024Article
- A survey in Austria supports the significance of genetic counseling and pharmacogenetic testing for mental illness.Frontiers in psychiatry · 2024Article
- Provider-reported experiences, barriers, and perspectives on genetic testing as part of autism diagnosis.PloS one · 2024Article
- The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review.Psychological medicine · 2023Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
The purpose of this study was to report current practices and attitudes of child and adolescent psychiatrists (CAP) regarding diagnostic genetic and pharmacogenetic (PGx) testing. We surveyed 958 US-based practicing CAP. 54.9% of respondents indicated that they had ordered/referred for a genetic test in the past 12 months. 87% of respondents agreed that it is their role to discuss genetic information regarding psychiatric conditions with their patients; however, 45% rated their knowledge of genetic testing practice guidelines as poor/very poor. The most ordered test was PGx (32.2%), followed by chromosomal microarray (23.0%). 73.4% reported that PGx is at least slightly useful in child and adolescent psychiatry. Most (62.8%) were asked by a patient/family to order PGx in the past 12 months and 41.7% reported they would order PGx in response to a family request. Those who ordered a PGx test were more likely to have been asked by a patient/family and to work in private practice. 13.8% of respondents agreed/strongly agreed that a PGx test can predict the effectiveness of specific antidepressants. Some respondents also indicated they would make clinical changes based on PGx information even if a medication was currently effective and there were no side effects. Genetic testing has become routine clinical care in child and adolescent psychiatry. Despite this, many providers rate their associated knowledge as poor/very poor. Patient requests were associated with ordering practices and providers misinterpretation of PGx may be leading to unnecessary changes in clinical management. There is need for further education and support for clinicians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.